

Norihiro Watanabe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6069946/publications.pdf>

Version: 2024-02-01

19
papers

1,267
citations

1040056

9
h-index

996975

15
g-index

19
all docs

19
docs citations

19
times ranked

1569
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. <i>Molecular Therapy</i> , 2017, 25, 249-258.	8.2	217
2	Armed Oncolytic Adenovirus Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. <i>Cancer Research</i> , 2017, 77, 2040-2051.	0.9	170
3	Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. <i>Molecular Therapy</i> , 2017, 25, 2440-2451.	8.2	151
4	Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor. <i>Molecular Therapy</i> , 2014, 22, 1211-1220.	8.2	145
5	Fine-tuning the CAR spacer improves T-cell potency. <i>Oncolmmunology</i> , 2016, 5, e1253656.	4.6	137
6	Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. <i>Cancer Discovery</i> , 2018, 8, 972-987.	9.4	93
7	CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. , 2018, 6, 34.		85
8	Engineered off-the-shelf therapeutic T cells resist host immune rejection. <i>Nature Biotechnology</i> , 2021, 39, 56-63.	17.5	71
9	Impact of Manufacturing Procedures on CAR T Cell Functionality. <i>Frontiers in Immunology</i> , 2022, 13, 876339.	4.8	54
10	Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. <i>Molecular Therapy</i> , 2021, 29, 505-520.	8.2	48
11	Modulating TNF activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. , 2020, 8, e001229.		29
12	Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. , 2021, 9, e003237.		29
13	Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. , 2019, 7, 330.		18
14	Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 387-397.	5.2	4
15	Off-the-Shelf Chimeric Antigen Receptor T Cells. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 176-181.	2.0	4
16	Generation of CAR T-cells using β -retroviral vector. <i>Methods in Cell Biology</i> , 2022, 167, 171-183.	1.1	4
17	Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy. <i>Cytotherapy</i> , 2022, 24, 282-290.	0.7	4
18	Overcoming the breast tumor microenvironment by targeting MDSCs through CAR-T cell therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1032-1032.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 22-23.	1.4	2